The 20S ginsenoside Rh2 (G-Rh2) effectively inhibits cancer cell growth and survival in both animal models and cell lines. However, its molecular targets and mechanism of action remain largely unknown. By screening for molecules that interact with (20S)G-Rh2 in a phage display assay, we have identified Annexin A2 as a potential target that mediates its anti-cancer activity. Isothermal titration calorimetry and a cellular thermal shift assay demonstrated that (20S)G-Rh2 directly bound to either recombinant or intracellular Annexin A2. This binding inhibited the interaction between Annexin A2 and the NF-кB p50 subunit, which attenuated the nuclear translocations of NF-кB p50 subunit and reduced the transactivation activity of NF-кB. Correspond to this result, (20S)G-Rh2 treatment significantly downregulated the expression of IAPs (inhibitors of apoptosis), the well-established NF-кB targets that promote cell survival. Moreover, (20S)G-Rh2 synergized with Annexin A2 inactivation to promote apoptosis. Taken together, this study for the first time suggests a cellular target and a molecular pathway by which (20S)G-Rh2 inhibits cancer cell growth. As over-expression of Annexin A2 was evident in human hepatoma, (20S)G-Rh2 might be a promising natural compound for targeted liver cancer therapy.
regulates the expression of various anti-apoptosis genes, including the inhibitor of apoptosis proteins (IAPs), anti-apoptosis members of the Bcl-2 superfamily, and other pro-survival genes, and these regulations promote drug resistance in pancreatic cancer, lung cancer, melanoma, gastric cancer, and hepatocellular carcinoma 16, [28] [29] [30] . Interestingly, some ginsenosides, like G-Rh2, G-Rg3, and compound K (CK), suppress NF-кB activity 11 . It is tempting to assume that the pro-apoptotic activity of ginsenosides may arise from NF-кB suppression.
In this study, we immobilized (20S)G-Rh2 onto PEGA (polyethylene glycol adipate) resin and performed a phage display to screen for cellular targets of (20S)G-Rh2. We identified 46 potential target genes including Annexin A2. We employed isothermal titration calorimetry and competitive G-Rh2-pulldown assays to assess the interaction between (20S)G-Rh2 and Annexin A2. Here, we demonstrated for the first time that (20S)G-Rh2 directly binds to Annexin A2, which interfered the interaction between Annexin A2 and NF-кB p50 subunit, and thus, down-regulated NF-кB activation and anti-apoptosis gene expression, finally promoted apoptosis in cancer cells.
Results
Primary screening of cellular targets of (20S)G-Rh2 by phage display. Five rounds of bio-panning were performed with the (20S/R)G-Rh2-PEGA resin and the T7 Select Human Liver Tumor cDNA phage library. In the fifth round, with an input of 1 × 10 11 pfu, the elution rates reached 6 × 10 % with the (20S)G-Rh2-PEGA and (20R)G-Rh2-PEGA resins, respectively (Tables 1 and S1 ). Sequences of 181 phage plaques collected by the (20S)G-Rh2-PEGA resin were amplified via PCR followed by gene sequencing. Among these, 95 sequences fell within protein coding regions, 47 sequences fell within non-coding regions, and the other 39 sequences did not belong to the human transcriptome. After filtering out the repeated hits, we finally identified 46 potential targets for (20S)G-Rh2 (Table S2) . Fortunately, Annexin A2, a multifunctional tumor-associated protein, was identified with (20S)G-Rh2-PEGA, but not (20R)G-Rh2-PEGA.
(20S)G-Rh2 bound directly to either recombinant or intracellular Annexin A2. To confirm the interaction between (20S)G-Rh2 and intact Annexin A2, we performed isothermal titration calorimetry with a purified recombinant full-length Annexin A2. The result showed that (20S)G-Rh2 bound to Annexin A2 in an equimolar ratio, with an association constant of 1.13 × 10 −5 M −1 and a binding free energy of −3.507 kJ/mol (Fig. 1a) . A competitive pull-down assay showed that both the endogenous Annexin A2 expressed in HepG2 cells and the purified recombinant Annexin A2 interacted with the (20S)G-Rh2-PEGA resin, and this interaction was remarkably reduced by free (20S)G-Rh2. In contrast, little binding was observed with the (20R)G-Rh2-PEGA resin, and no change was observed after adding free (20R)G-Rh2 (Fig. 1b) .
The nucleotide sequence of Annexin A2 obtained from the phage display encoded amino acids 143 to 308 within the Annexin A2 protein, covering the entire domain III and parts of domains II and IV ( Figure S1a ). Next, we performed a molecular docking analysis, based on the published crystal structure of Annexin A2 (PDB ID: 2HYU). The optimum binding site for (20S)G-Rh2 was located within domain IV of Annexin A2 and three amino acid residues were involved in the interaction with (20S)G-Rh2: the ε-amino group of Lys302 and the amino groups of Asp299 and Glu297 (Fig. 1c) . A competitive pull-down assay with the K302A mutant of Annexin A2 (Annexin A2-K302A) showed that the mutant did not interact with (20S)G-Rh2-PEGA resin, either when Annexin A2-K302A was over-expressed in HEK-293T cells or when it was expressed and purified from prokaryotic cells (Fig. 1d) . These data suggest that (20S)G-Rh2 directly and specifically bound to Annexin A2 and Lys302 was a critical amino acid residue for this binding.
To examine whether (20S)G-Rh2 can interact with intracellular Annexin A2, we performed cellular thermal shift assays in HepG2 cells. The temperature that elicited a half-maximal thermal response (T m 50) for Annexin A2 shifted from 47.5 °C to 57.2 °C, after adding (20S)G-Rh2 (Fig. 1e, Table S4 ). Next, we tested Annexin A2 obtained by transfecting a vector that carried c-myc fused to either the wild-type Annexin A2 (Annexin A2-WT) or K302A mutant of Annexin A2 (Annexin A2-K302A) in HEK-293T cells. (20S)G-Rh2 caused the T m 50 of Annexin A2-WT to shift from 49.48 °C to 58.44 °C, but the T m 50 of the Annexin A2-K302A remained stable at around 48 °C (Figs 1e and S1b). Taken together, these data demonstrated that Annexin A2 was a target of (20S) G-Rh2.
(20S)G-Rh2 inhibited NF-кB activation and down-regulated anti-apoptosis gene expression. Previous study has shown that Annexin A2 up-regulates the transcription activity of NF-κB by binding to and facilitating nuclear translocation of the p50 subunit of NF-кB 16 . Moreover, the anti-apoptosis genes, including c-IAP1, c-IPA2, X-IAP, Survivin, and Bcl-xL were regulated by NF-κB 31 , leading us to speculate that the binding of (20S)G-Rh2 to Annexin A2 might modulate Annexin A2-mediated NF-кB activation and expression of these anti-apoptosis proteins. To examine this possibility, we performed a luciferase reporter gene assay showing that (20S)G-Rh2 (1.875 μg/mL and 3.75 μg/mL) effectively inhibited NF-кB activation in a dose dependent manner, both in the resting state and during NF-кB activation stimulated by 100 ng/mL PMA or 25 μg/ mL etoposide ( 
(20S)G-Rh2 inhibited Annexin A2 binding to NF-кB p50 subunit. To test whether the inhibition of NF-кB activity by (20S)G-Rh2 in HepG2 cells was resulted from the attenuated interaction between Annexin A2
and NF-кB p50 subunit, we performed an immunoprecipitation after cells were treated with 3.75 μg/mL (20S) G-Rh2 without or with NF-кB activators, PMA (100 ng/mL) or etoposide (25 μg/mL). The interaction between Annexin A2 and NF-кB p50 significantly inhibited with (20S)G-Rh2 treatment, both in resting cells and NF-кB activator treated cells, in which the interaction was largely enhanced (Fig. 3a) . To rule out the possibility that other mammalian proteins may mediate the inhibitory effect of (20S)G-Rh2 on the interaction between Annexin A2 and NF-кB p50 subunit, we expressed Annexin A2 and NF-кB p50 subunit in E. coli BL21, and performed immunoprecipitation with these cell lysates. Prokaryotic cell-expressed Annexin A2 and NF-кB p50 subunit bound to each other, and their interaction was also inhibited largely by (20S)G-Rh2 (Fig. 3b) . Next, we examined whether the nuclear localization of the Annexin A2 and NF-кB p50 subunit was inhibited by (20S)G-Rh2 treatment. Either immune-blot or immunofluorescence clearly showed that the nuclear localization of Annexin A2 and NF-кB p50 subunit were significantly inhibited in the resting cells and in NF-кB activator stimulated cells with (20S)G-Rh2 treatment ( Fig. 3c and d ). Taken together, we suggest that binding of (20S) G-Rh2 to Annexin A2 effectively inhibited the interaction between Annexin A2 and NF-кB p50 subunit, and their nuclear localization.
Annexin A2-knockdown enhanced (20S)G-Rh2-induced apoptosis. Next we examined whether the inactivation of Annexin A2 by gene knockdown reduced NF-кB activity in HepG2 cells, as previously observed in pancreatic cancer cells 16 . The report gene assay showed that NF-кB activity significantly down-regulated in Annexin A2-knockdown HepG2 cells compared to control cells, under both resting state and treatment of NF-кB activator (Fig. 4a) . The expression of NF-кB-regulated genes including c-IAP1, c-IAP2, X-IAP, Survivin, IL-2, and IL-6 were also obviously down-regulated in Annexin A2-knockdown cells ( Figure S3a ). Because, (20S)G-Rh2 effectively inhibited the formation of Annexin A2-p50 complex and NF-кB activation, we asked whether (20S)G-Rh2 synergized with the Annexin A2 knockdown to inhibit NF-кB activation and the expression of downstream genes. As expected, the inhibitory effect of (20S)G-Rh2 on NF-кB activity was dramatically enhanced in Annexin A2-knockdown cells compared to that of control cells (Fig. 4a) . Similarly, (20S) G-Rh2-induced down-regulation of c-IAP1, c-IAP2, X-IAP, Survivin, and IL-6 was much more significant in Annexin A2-knockdown cells than that of control cells (Fig. 4b) . Next we compared cell viability of Annexin A2-knockdown cells to that of control cells upon (20S)G-Rh2 treatment. The results showed that the survival rate of Annexin A2-knockdown cells was obviously lower than that of control cells with (20S)G-Rh2 treatment (Fig. 4c, Table 2 ). The activation of both caspase 3 and 9 was much more evident in Annexin A2-knockdown cells than that of control cells upon (20S)G-Rh2 treatment (Figs 4d and S4b). In addition, PARP cleavage occurred at a lower (20S)G-Rh2 concentration in Annexin A2-knockdown cells, compared to control cells (Fig. 4b) . Thus, silencing of Annexin A2 rendered cells largely sensitive to (20S)G-Rh2 treatment.
K302A mutant of Annexin A2 was resistant to (20S)G-Rh2 effect.
To provide further evidence for the notion that the inhibitory effect of (20S)G-Rh2 on NF-кB activity is mediated by the direct binding of (20S) G-Rh2 to Annexin A2 protein. For this end, we examined whether over-expression of Annexin A2-K302A rendered cells resistant to (20S)G-Rh2 triggered signal transductions, including the interaction between Annexin A2 and NF-кB p50, and their nuclear localization, as well as the subsequent NF-кB activation in HepG2 cells. The interaction between Annexin A2 and NF-кB p50 subunit and nuclear localization of these two proteins were evidently inhibited by (20S)G-Rh2 treatment in wild-type Annexin A2-over-expressed HepG2 cells. By contrast, neither the interaction between Annexin A2-K302A and NF-кB p50 subunit nor their nuclear localization was down-regulated by (20S)G-Rh2 treatment, indicating that the binding of (20S)G-Rh2 to Annexin A2 was critical to inhibit the interaction between Annexin A2 and NF-кB p50 subunit and subsequent their nuclear localization (Fig. 5a,b) . The interaction between Annexin A2-K302A and NF-кB p50 subunit was increased to an extent by (20S)G-Rh2 treatment in Annexin A2-K302A transfectants (Fig. 5a ). NF-кB activity was inhibited in a dose-dependent manner in wild-type Annexin A2 transfected cells with (20S)G-Rh2 treatment. By contrast, HepG2 cells with normal Annexin A2 levels (sh-NC) or low Annexin A2 levels (sh-Annexin A2) exposed to low concentrations of (20S)-G-Rh2. All data are shown as the mean ± SD *P < 0.05, **P < 0.01, and ***P < 0.001 and the experimental points show the average of at least triplicates. All experiments were repeated at least 3 times. Statistical analyses were performed using Student's t-test. over-expression of Annexin A2-K302A abolished the inhibitory effect of (20S)G-Rh2 on NF-кB activity (Fig. 5c) . These data suggest that (20S)G-Rh2 down-regulates NF-кB activity mainly by targeting Annexin A2 in HepG2 cells.
Our next goal was to provide evidence for the notion that Annexin A2 is an important target protein of (20S)G-Rh2 to execute its anti-cancer activity. For this end, we examined whether ectopic over-expression of Annexin A2-K302A rendered HepG2 cells resistant to (20S)G-Rh2-induced cell death more efficiently than over-expression of wild-type Annexin A2. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay showed that the IC 50 of (20S)G-Rh2 increased ~2-fold in wild-type Annexin A2 transfectants, and ~3-fold in Annexin A2-K302A transfectants, respectively, relative to control cells (Fig. 5d, Table 3 ). Plate clone formation assay also clearly showed that Annexin A2-K302A transfectants prevented (20S)G-Rh2 induced cell death much more significantly than wild-type Annexin A2 transfectants (Fig. 5e) , suggesting that the anti-survival activity of (20S)G-Rh2 on cancer cell was primarily executed by targeting Annexin A2 in HepG2 cells.
Discussion
(20S)G-Rh2 has been suggested to inhibit cancer development, progression, and metastasis [7] [8] [9] [10] . Our previous study showed that (20S)G-Rh2 triggered the mitochondrial translocation of Bax and Bak, promoted cytochrome c release, and initiated caspase 9-dependent apoptosis 4, 32 . (20S)G-Rh2 also induced p53 activation, and triggered caspase 8-dependent apoptosis, by up-regulating Fas 10 . A number of studies suggested that (20S)G-Rh2-induced apoptosis was associated with the activation of cyclin A-Cdk2, PKC-delta, and JNK1 4, 5, 11 . Thus, (20S)G-Rh2 is likely to interact with multiple cellular targets, and it modulates numerous signal transduction pathways. Because, the epimer of (20S)G-Rh2, (20R)G-Rh2, exhibited little cytotoxicity in tumor cells 4, 9 , the target specificity of (20S) G-Rh2 should determine its distinct functions. Therefore, exploring the cellular targets of (20S)G-Rh2 is a key approach to understand its efficacy and mechanism of action.
Here, we performed a phage display, a systematic method widely used for the discovery of small moleculeprotein interactions. We screened for proteins that showed pivotal interactions with (20S)G-Rh2, using (20R) G-Rh2 as a negative control. Fortunately, we found Annexin A2, a cancer-promoting protein, which could specifically bind to the (20S)G-Rh2-PEGA resin, but not the (20R)G-Rh2-PEGA resin. We demonstrated the interaction between (20S)G-Rh2 and purified Annexin A2 by an isothermal titration calorimetry assay (Fig. 1a) . The competitive pulldown assays further confirmed that both endogenous and purified Annexin A2 specifically bound to (20S)G-Rh2 (Fig. 1b) , but little interaction was observed between Annexin A2 and (20R)G-Rh2. Molecular docking suggested that the optimum binding site of (20S)G-Rh2 was located in a groove within domain IV of Annexin A2, in addition, lys302 was a key amino acid in the interaction (Figs 1c and S1a). In another competitive pulldown assay with the mutant version of Annexin A2, Annexin A2-K302A, we demonstrated that the mutation at lys302 caused the loss of (20S)G-Rh2 binding (Fig. 1d) . In addition, a cellular thermal shift assay showed that (20S)G-Rh2 could bind to Annexin A2 in living cells (Figs 1e and S1b). Those results demonstrated that Annexin A2 was a cellular target of (20S)G-Rh2 and that lys302 was a key amino acid in the engagement between Annexin A2 and (20S)G-Rh2.
Annexin A2 plays multiple roles in tumor cell proliferation and metastasis [16] [17] [18] [19] [20] [21] . A previous report has indicated that intracellular Annexin A2 functioned as an anti-apoptosis factor and enhanced drug resistance by interacting with NF-кB p50 subunit 16 . Thus, the interaction between Annexin A2 and (20S)G-Rh2 may be linked functionally to the NF-кB pathway within a cell. As expected, (20S)G-Rh2 inhibited NF-кB activation in human liver cancer HepG2 cells even in the presence of NF-кB activators, either etoposide or PMA (Fig. 2a) . A typical target gene of NF-кB, IL-6, and important anti-apoptosis genes, including c-IAP-1, c-IAP-2, X-IAP, and Survivin, which were also regulated by NF-кB were down-regulated by (20S)G-Rh2 (Figs 2b and S2a,b ). An immunoprecipitation assay demonstrated that the interaction between Annexin A2 and NF-кB p50 subunit was significantly inhibited by (20S)G-Rh2 (Fig. 3a) . Another immunoprecipitation assay with E. coli cell lysate expressing recombinant Annexin A2 and NF-кB p50 subunit also showed that (20S)G-Rh2 inhibited their interactions, indicating that the inhibitory effect of (20S)G-Rh2 on the formation is executed without any other mammalian protein (Fig. 3b) . Further, the nuclear translocation of either Annexin A2 or NF-кB p50 subunit was also significantly inhibited by (20S)G-Rh2 (Fig. 3c,d ), which could directly affect the transcriptional activity of NF-кB. To determine whether (20S)G-Rh2 inhibited NF-кB activation in an Annexin A2-dependent manner, we performed gene silencing or over-expression of Annexin A2, followed by (20S)G-Rh2 treatment. The results showed that down-regulation of Annexin A2 restricted NF-кB activation and showed synergistic effects with (20S)G-Rh2 (Figs 4a and S3b) . However, the over-expression of Annexin A2-K302A promoted nuclear translocation of NF-кB p50 subunit and prevented (20S)G-Rh2-induced NF-кB inhibition regardless of (20S)G-Rh2 (Fig. 5a,b) . Taken together, these results indicated that (20S)G-Rh2 induced NF-кB suppression mainly by targeting Annexin A2.
To study Annexin A2-mediated anti-cancer activity of (20S)G-Rh2, we conducted MTT and plate clone formation assay. Either over-expression of wild-type Annexin A2 or that of Annexin A2-K302A rendered HepG2 cells resistant to cell death induced by (20S)G-Rh2 treatment. Importantly, the resistant effect was more evident IC50 of (20S)G-Rh2(μg/mL) sh-NC sh-Annexin A2 Table 2 . IC50 of (20S)G-Rh2 in HepG2 cells that expressed Annexin A2 at control (sh-NC) or low levels (shAnnexin A2). 3 per well) are plated onto 96-well plate and exposed to the indicated concentrations of (20S)G-Rh2. Then cells are cultured for 72 h followed by MTT assay. All data are shown as the mean ± SD and the experimental points show the average of at least triplicates. All experiments were repeated at least 3 times.
IC50 of (20S)G-Rh2(μg/mL)
HepG2/vector 1.648
HepG2/Annexin A2-WT 2.879*** HepG2/Annexin A2-K302A 4.412*** Table 3 . IC50 of (20S)G-Rh2 in HepG2 cells that expressed wide type and K302A mutant of Annexin A2.
in Annexin A2-K302A transfectants than that of wild-type Annexin A2 transfectants (Fig. 5d ,e, and Table 3 ). By contrast, silencing of Annexin A2 rendered cells much more sensitive to (20S)G-Rh2-induced apoptosis (Figs 4b-d and S4d). Annexin A2 is over-expressed in several cancer cell lines, and it promotes cancer cell survival and metastasis 12 . To check the Annexin A2 expression in human hepatoma, we analyzed published patients' data via Oncomine (http://www.oncomine.org), a free online bioinformatic resource of cancer transcriptome data. It collects clinical mRNA array data of different genes from different patients all over the world. As shown in Figure S6a , Annexin A2 mRNA level was significantly elevated in hepatocellular carcinoma (P < 0.001) and the ROC curve generated based on the mRNA level of Annexin A2 indicated that Annexin A2 can be a biomarker of high accuracy (AUC > 0.9) in hepatocellular carcinoma ( Figure S6b ). The inhibition of Annexin A2 by gene silencing or small chemical inhibitors, like Withaferin A, significantly reduced cancer cell growth and tumor metastasis 33 . Thus, Annexin A2 might be an important target protein, and (20S)G-Rh2 is a promising natural compound for anti-hepatoma therapies.
In summary, we demonstrated that (20S)G-Rh2 directly bound to Annexin A2, which inhibited the interaction between Annexin A2 and NF-кB p50 subunit. This interference promoted apoptosis by inhibiting NF-кB activity and down-regulating anti-apoptosis gene expression. This study was the first to identify the cellular target of (20S)G-Rh2, and we revealed how (20S)G-Rh2 promoted apoptosis in cancer cells.
Materials and Methods
Cell lines, reagents, and plasmids. HepG2, and HEK-293T cells were obtained from the American Type Culture Collection (ATCC, Rockville, MA, USA). Dulbecco's Modified Eagle Medium (DMEM) was obtained from Gibco BRL (Grand Island, NE, USA). The following reagents were used: (20S)G-Rh2 (Sigma), (20R)G-Rh2 (Sigma), phorbol myristate acetate (PMA. Sigma), and etoposide (Sigma). The ginsenosides were dissolved in 75% alcohol. PMA and etoposide were dissolved in DMSO. For use in phage display, we purchased the T7 select human liver tumor cDNA phage library and host Escherichia coli BLT5615 bacteria cells from Millipore (MA, USA.). We used the following primary antibodies: rabbit anti-PARP (Santa Cruz), rabbit anti-c-IAP1 (Santa Cruz), rabbit anti-NF-кB p50 subunit (Santa Cruz), rabbit anti-PCNA (Santa Cruz), rabbit anti-myc (Santa Cruz), rabbit anti-cleaved caspase 3 (Cell Signaling), rabbit anti-cleaved caspase 9 (Cell Signaling), mouse anti-Annexin A2 (Santa Cruz), mouse anti-Survivin (Santa Cruz), mouse anti-β-actin (Santa Cruz), mouse anti-α-tubulin (Santa Cruz), mouse anti-X-IAP (Santa Cruz), and mouse anti-c-IAP2 (Cell Signaling). We used the following secondary antibodies: HRP-conjugated goat anti-mouse IgG (Pierce), HRP-conjugated goat anti-rabbit IgG (Pierce), Cy ™ 3 affinipure donkey anti-mouse IgG (Jackson ImmunoResearch Inc., PA, USA), and Alexa Fluor ® 488 affinipure donkey anti-Rabbit IgG (Jackson ImmunoResearch Inc., PA, USA). We synthesized the genes that encoded human Annexin A2 and human NF-кB p50 subunit with PCR, and we cloned the sequences into the pEXS-CG vector (provided by Professor Fei Sun's group, at the Institute of Biophysics of Chinese Academy of Sciences). The resulting prokaryotic vectors allowed expression of non-tagged Annexin A2 (pEXS-Annexin A2), non-tagged NF-кB p50 subunit (pEXS-p50), and C-terminal GST-tagged Annexin A2 (pEXS-CG-Annexin A2). To prepare Annexin A2 mutant, we engineered a single point mutation within the pEXS-CG-Annexin A2 construct, and the result was called pEXS-CG-Annexin A2-K302A. We also constructed eukaryotic vectors that carried c-myc fused to the wild-type Annexin A2 (pcs4-Annexin A2-WT-myc) and c-myc fused to the K302A mutant of Annexin A2 (pcs4-Annexin A2-K302A-myc). We used the short hairpin RNA (shRNA) vector, pGPU6-GFP-Neo-Annexin A2, to create shRNA-Annexin A2 gene silencers, which knocked down Annexin A2 expression to different degrees in RNA interference assays (GenePharma, Jiangsu, China). The luciferase reporter gene assays were performed with the following plasmids: pNFκB-TA-luc (Beyotime, Shanghai, China) and pRL-CMV (Promega, WI, USA).
Synthesis of ginsenoside (20S/R)G-Rh2-PEGA resin.
We washed 750 mg of amino PEGA resin (Millipore, MA, USA) three times with pyridine, and added 0.33 mmol of nitrophenyl bromoacetate (Alfa Aesar, MA, USA). The resin was stirred at room temperature for 3 h, filtered, and washed three times with 10 mL each of dichloromethane (CH 2 Cl 2 ), MeOH, and N, N-dimethylformamide (DMF). The brominated PEGA resin was mixed with 0.3 mmol (20S)G-Rh2 and 0.3 mmol K 2 CO 3 in DMF. The mixture was stirred at room temperature for 3 days, filtered, and washed three times with 10 mL MeOH. We prepared (20R)G-Rh2-PEGA resin in the same way. The PEGA resins were balanced with TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.1% TWEEN-20) before use.
Phage display screening. We performed phage display screening with the T7 Select Human Liver Tumor cDNA phage library (Millipore, MA, USA). The original library was amplified by infecting host cells with up to 10 11 phage forming units (pfu)/mL. Then, 1 mL of amplified phage was incubated with 100 μL native PEGA resin overnight at 4 °C to break non-specific bonds. Next, 800 μL of pre-cleared phage was mixed with 200 μL (20S) G-Rh2-PEGA resin or (20R)G-Rh2-PEGA resin, and incubated overnight at 4 °C. The resin was washed three times with 1 mL of TBST for three times and incubated with 200 μL elution buffer (1% SDS) for 30 min at room temperature with gentle shaking. Next, 5 μL of the eluted fraction was inoculated into 5 mL of E. coli BLT5615 cells and incubated for 3 h at 37 °C. Phage-infected cells were mixed with NaCl to a final concentration of 0.5 M and centrifuged at 800 × g for 5 min. The supernatants were utilized for subsequent bio-panning. The number of pfu was determined by performing a phage titer, before the bio-panning step, according to the manufacturer's protocol.
Sequence analysis of selected phage recombinants. After the final bio-panning step, phages were diluted to obtain an individual plaque. The plaques were resuspended in 100 μL of lysis buffer (10 mM EDTA, pH 8.0), heated at 65 °C for 10 min, and briefly vortexed. The lysate was cooled down to room temperature and centrifuged at 12,000 × g at 4 °C for 3 min. The supernatant served as a PCR template, and amplification
